GlassScriptPhysician profile
Donna Geiger
NPI 1356853378
$2,847.59
in general payments reported to CMS, 2019-2025
33 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $518 · 2022: $464 · 2023: $282 · 2024: $404 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,865.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $461.55 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Solventum Corporation | $321.65 | 2024-2025 | Activ.A.C., Prevena, V.A.C.Instill |
| Merck Sharp & Dohme LLC | $279.64 | 2021-2025 | Winrevair, Verquvo |
| Medtronic, INC. | $212.81 | 2021-2024 | Linq II |
| Organogenesis INC. | $181.61 | 2023-2025 | Puraply, Puraply Wound Matrix, Affinity |
| Cvrx, INC. | $167.98 | 2022-2025 | Barostim Neo System |
| Integra Lifesciences Corporation | $163.31 | 2021-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Abbvie INC. | $121.93 | 2021-2022 | |
| Abbott Laboratories | $119.66 | 2025 | Xact |
| Relievant Medsystems, INC. | $114.66 | 2021 | |
| Smith+Nephew, INC. | $75.04 | 2021-2025 | Collagenase Santyl, Grafix Pl |
| Astrazeneca Pharmaceuticals LP | $74.91 | 2021-2024 | Wainua |
| Convatec INC. | $74.63 | 2025 | |
| Philips North America LLC | $41.77 | 2023-2024 | (Ck4) Mcot |
| Pulmonx Corporation | $40.80 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.83 | 2023-2025 | Lifevest |
| Glaxosmithkline, LLC. | $36.50 | 2022-2023 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $28.78 | 2022 | |
| Mallinckrodt Hospital Products INC. | $28.15 | 2023 | Acthar |
| Pfizer INC. | $27.92 | 2022-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $25.38 | 2024 | Arcalyst |
| United Therapeutics Corporation | $23.76 | 2022 | |
| Urgo Medical North America, LLC | $22.81 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Kci USA, INC. | $21.11 | 2021 | |
| Impulse Dynamics (USA) INC. | $19.81 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.32 | 2025 | Amvuttra |
| Gilead Sciences, INC. | $18.53 | 2021 | |
| Novo Nordisk INC | $16.80 | 2021 | |
| Reprise Biomedical, INC. | $15.63 | 2022 | |
| Grifols USA, LLC | $14.89 | 2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.29 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $12.76 | 2023 | Arcalyst |
| Kerecis Limited | $10.37 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Geiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.